Next-Generation Combination Therapy In Oncology

By Aidan Finley (Contributor), Vivek Mittal (Contributor) / Email the Authors / IN VIVO November 2011, Vol. 29, No. 10
Feature Articles / Word Count: 5207 / Article # 2011800186

Executive Summary

Despite significant scientific advances tied to the molecular understanding of cancer, clinical advances have been more limited, largely because the complexity of most tumors defies novel single-target approaches. Clinical advances in the future will require developing rational combinations of targeted therapeutics, as well as leveraging advances in biomarkers and clinical trial design. Vetting new targets with a biomarker, pursuing them in combination trials with several targeted agents, and efficiently moving the resulting rational combination through development to regulatory approval will be the roadmap for commercial success.